Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Sheahan

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Cell Reports|July 16, 2020
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Science Translational Medicine|April 8, 2020
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceTimothy P Sheahan, Amy C Sims, Shuntai Zhou, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in miceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialDavid R Martinez, Fernando R Moreira, Mark R Zweigart, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
Scientific Data|April 2, 2024
A compendium of multi-omics data illuminating host responses to lethal human virus infectionsAmie J Eisfeld, Lindsey N Anderson, Shufang Fan, et al.
Cell Reports|November 6, 2024
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoNian E Zhou, Su Tang, Xuelin Bian, et al.
Science Translational Medicine|May 22, 2024
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronavirusesDavid R Martinez, Fernando R Moreira, Nicholas J Catanzaro, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesAlexandra C Walls, Marcos C Miranda, Minh N Pham, et al.
Biorxiv : the Preprint Server for Biology|August 21, 2020
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Alexandra C Walls, Brooke Fiala, Alexandra Schäfer, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cell Reports|July 16, 2020
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Science Translational Medicine|April 8, 2020
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceTimothy P Sheahan, Amy C Sims, Shuntai Zhou, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in miceAndrea J Pruijssers, Amelia S George, Alexandra Schäfer, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialDavid R Martinez, Fernando R Moreira, Mark R Zweigart, et al.
Nature Medicine|August 18, 2022
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2Rachel J Hagey, Menashe Elazar, Edward A Pham, et al.
Scientific Data|April 2, 2024
A compendium of multi-omics data illuminating host responses to lethal human virus infectionsAmie J Eisfeld, Lindsey N Anderson, Shufang Fan, et al.
Cell Reports|November 6, 2024
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoNian E Zhou, Su Tang, Xuelin Bian, et al.
Science Translational Medicine|May 22, 2024
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronavirusesDavid R Martinez, Fernando R Moreira, Nicholas J Catanzaro, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesAlexandra C Walls, Marcos C Miranda, Minh N Pham, et al.
Biorxiv : the Preprint Server for Biology|August 21, 2020
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Alexandra C Walls, Brooke Fiala, Alexandra Schäfer, et al.
Pageof 9